4//SEC Filing
Dorval Allison 4
Accession 0000950170-24-132799
CIK 0001840574other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 4:30 PM ET
Size
9.0 KB
Accession
0000950170-24-132799
Insider Transaction Report
Form 4
Dorval Allison
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-29+1,875→ 5,935 total - Sale
Common Stock
2024-12-02$5.64/sh−555$3,130→ 5,380 total - Exercise/Conversion
Restricted Stock Units
2024-11-29−1,875→ 1,875 total→ Common Stock (1,875 underlying)
Footnotes (3)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date,
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 9, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F3]On November 29, 2021, the reporting person was granted 7,500 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on November 29, 2022 and the remainder vesting in equal annual installments until November 29, 2025.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001625110
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 4:30 PM ET
- Size
- 9.0 KB